2022. Lymphoproliferative skin lesion as a previously unreported adverse event detected in a patient receiving mSTR TB treatment. Journal of Pharmacovigilance and Drug Research. 3, 2 (Jun. 2022), 34–37. DOI:https://doi.org/10.53411/jpadr.2022.3.2.7.